TLR9-Agonistic DNA Aptamer
View DOI ↗Molecular and functional characterization of a novel Toll-like receptor 9-specific DNA aptamer with therapeutic potential
Farooq et al. · International Immunopharmacology · 2026 · 172:116134
Publications & Intellectual Property
The research behind our programs
Selected publications spanning immune signaling and regenerative peptide research, with direct links to the scientific record.
MyD88 Inhibitory Peptide
View DOI ↗Rational design and therapeutic potential of MyD88 inhibitory peptide in psoriasis
Farooq et al. · Biomedicine & Pharmacotherapy · 2025 · 183:117801
NLRP3 Inhibition
View DOI ↗Novel Small-Molecule Inhibitor of NLRP3 Inflammasome Reverses Cognitive Impairment in an Alzheimer's Disease Model
Haseeb et al. · ACS Chemical Neuroscience · 2022 · 13(6):818–833
Endosomal TLR Inhibition
View DOI ↗Discovery of ETI41 and ETI60: novel selective endosomal Toll-like receptor inhibitors for the treatment of autoimmune diseases
Jeong et al. · Experimental & Molecular Medicine · 2025 · 57:1951–1962
FGFR-Agonistic Peptide
View DOI ↗Identification of a novel fibroblast growth factor receptor-agonistic peptide and its effect on diabetic wound healing
Farooq et al. · Life Sciences · 2025 · 364:123432
VEGFR2-Agonistic Peptide
View DOI ↗AI-assisted design of a VEGFR2 agonistic peptide that promotes angiogenesis and wound repair
Yasmeen et al. · Protein Science · 2026 · e70529
Substance P Analog
View DOI ↗Endogenous Stem Cell-Based In Situ Tissue Regeneration Using Electrostatically Interactive Hydrogel with a Newly Discovered Substance P Analog and VEGF-Mimicking Peptide
Park et al. · Small · 2021 · 17(40):e2103244
SDF-1-Mimetic Peptide
View DOI ↗In-situ wound healing by SDF-1-mimic peptide-loaded click crosslinked hyaluronic acid scaffold
Kim et al. · Journal of Controlled Release · 2023 · 364:420–434
Intellectual property
Program-specific discussions
For potential collaborations, we welcome discussion of intellectual property relevant to a specific program. Publication does not by itself establish company ownership, availability or exclusivity of rights.
Discuss a program ↗